| Ytd | -11.22% | |
| 1y | -17.80% |
| Open | 2.78 | Prev Close | 2.76 | Low | 2.69 | High | 2.79 | Mkt Cap | 96.30M |
| Vol | 315.23K | Avg Vol | 301.10K | EPS | -0.32 | P/E | N/A | Forward P/E | -7.17 |
| Beta | 0.85 | Short Ratio | 3.03 | Inst. Own | 17.46% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-09 | 50-d Avg | 3.30 | 200-d Avg | 3.10 | 1yr Est | 8.50 |
SAN JOSE, Calif., Sept. 16, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company")
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.08) per share which beat the analys
SAN JOSE, Calif., Sept. 9, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (
Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co
Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined i
Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with
Anixa Biosciences (ANIX) might move higher on growing optimism about its earnings prospects, which i
HTLD, YEXT, ANIX, WVE and LCNB have been added to the Zacks Rank #1 (Strong Buy) List on July 22, 20
Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market s
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology c
Notice of Acceptance marks first Australian patent covering Anixa's breast cancer vaccine platform C
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology c
Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limitin
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co
Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in South
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co
Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints w
Anixa advances cancer vaccines and CAR-T therapies, supported by positive early data, a planned phas
Ovarian cancer CAR-T therapy, lira-cel, presentation to highlight positive survival observations fro
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.07) per share which beat the analys
Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the preven
Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the preven
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co
Multiple patients have survived substantially beyond expected median survival, including onepatient
SAN JOSE, Calif., May 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NA
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co
Expands global intellectual property coverage in markets with greater late-stage breast cancerdiagno
Lira-cel continues to exhibit positive survival data in ongoing Phase 1 clinical trialSAN JOSE, Cali
Lira-cel continues to exhibit positive survival data in ongoing Phase 1 clinical trial SAN JOSE, Cal
AVAX Technologies (OTCMKTS:AVXT - Get Free Report) and Anixa Biosciences (NASDAQ: ANIX - Get Free Re
Breast cancer vaccine met primary endpoints and generated protocol-defined immuneresponses in 74% of
Phase 1 study met primary endpoints, showed safety and tolerability at the maximum tolerated dose, a
Dr. Robert Wenham of Moffitt Cancer Center and principal investigator of the trial to present lira-c
Notice of Allowance marks first Korean patent covering Anixa's breast cancer vaccine platformExp
Multiple patients substantially exceed expected survival at low dose levels; absence of dose-limitin
Anixa Biosciences shares new data from its ovarian cancer trial, showing patients lived longer than
The ongoing Phase 1 trial is enrolling adult women with recurrent ovarian cancer, who have failed st
D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and m
On Tuesday, 647 companies set new 52-week lows.
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
During Tuesday's session, 454 stocks hit new 52-week lows.
Gainers AMC Entertainment Holdings, Inc. (NYSE: AMC) shares surged 23.7% to close at $12.77. Mo
Before 10 a.m. ET on Thursday, 239 stocks hit new 52-week highs.
Before 10 a.m. ET on Friday, 571 companies hit new 52-week highs.
Gainers
Gainers Immutep Limited (NASDAQ: IMMP) shares jumped 198.6% to $6.42 after the company said its C